{"id":"https://openalex.org/W61385997","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","title":"Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).","display_name":"Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W61385997","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","mag":"61385997"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.1073","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W61385997"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113604439","display_name":"WJ Gradishar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. J. Gradishar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058791215","display_name":"Florence Dalenc","orcid":"https://orcid.org/0000-0002-9854-4182","observed_orcids":["https://orcid.org/0000-0002-9854-4182"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Dalenc","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047918797","display_name":"Virginia Kaklamani","orcid":"https://orcid.org/0000-0002-3313-8458","observed_orcids":["https://orcid.org/0000-0002-3313-8458"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. G. Kaklamani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054878052","display_name":"F. Costa","orcid":"https://orcid.org/0009-0003-1670-3771","observed_orcids":["https://orcid.org/0009-0003-1670-3771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Costa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041874883","display_name":"T. P. Sahoo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. P. Sahoo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089088241","display_name":"J. G. M. Segalla","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Segalla","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053718144","display_name":"D. Lokanatha","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Lokanatha","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017447497","display_name":"H\u00e9lio Pinczowski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Pinczowski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101897724","display_name":"V. Raina","orcid":"https://orcid.org/0009-0000-2754-5324","observed_orcids":["https://orcid.org/0009-0000-2754-5324"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. Raina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Baselga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"1073","last_page":"1073"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.47749999165534973,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.47749999165534973,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.38109999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.03819999843835831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.8970000147819519},{"id":"https://openalex.org/keywords/locally-advanced-or-metastatic-breast-cancer","display_name":"locally advanced or metastatic breast cancer","score":0.8600000143051147},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9890000224113464},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9909999966621399},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":1.0},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7139999866485596},{"id":"https://openalex.org/keywords/covariate-imbalance","display_name":"covariate imbalance","score":0.7129999995231628},{"id":"https://openalex.org/keywords/treatment-effect-estimation","display_name":"treatment effect estimation","score":0.4090000092983246},{"id":"https://openalex.org/keywords/multivariate-analysis","display_name":"multivariate analysis","score":0.48500001430511475},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.4359999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8645668029785156},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6920581459999084},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6761184930801392},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.5275667905807495},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4740999639034271},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4640321731567383},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44312334060668945},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4316471219062805},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4253280758857727},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4103277325630188},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.39218950271606445},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3334546983242035},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32674288749694824},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.314300000667572},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07867613434791565},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.1073","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.1073","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2050516500","https://openalex.org/W2024765926","https://openalex.org/W2241823191","https://openalex.org/W2029641253","https://openalex.org/W2063280733","https://openalex.org/W2021468580","https://openalex.org/W2048627371","https://openalex.org/W2003999835","https://openalex.org/W2264912071","https://openalex.org/W2350984935"],"abstract_inverted_index":{"1073":[0],"Background:":[1],"Two":[2],"phase":[3,244,263],"IIb":[4,245],"trials":[5,248],"in":[6,80,215,227,242],"pts":[7],"with":[8,77,102,136,208,220,238],"advanced":[9,108,141,246],"BC":[10,109,142,247],"demonstrated":[11],"activity":[12],"for":[13,18,29,52,107,140,176,203,253],"SOR":[14,30,53,125,156,239,269,302,346],"plus":[15],"standard":[16],"chemotherapy":[17],"the":[19,88],"primary":[20],"endpoint":[21],"of":[22,90,121,168,186,234,266],"PFS.":[23,96],"In":[24,47,68],"Study":[25,48,98,132,216,228,280,308],"A,":[26,217],"median":[27,50],"PFS":[28,51,169,235],"+":[31,54,124,155],"capecitabine":[32],"(CAP)":[33],"versus":[34,38,57,61,240],"PL+CAP":[35,214],"was":[36,59,72,206,249],"6.4":[37],"4.1":[39],"mo":[40,63],"(hazard":[41],"ratio":[42],"[HR]":[43],"0.58;":[44],"1-sided":[45,66,197],"p=0.0006).":[46],"B,":[49],"paclitaxel":[55],"(PAC)":[56],"PL+PAC":[58,226],"6.9":[60],"5.6":[62],"(HR":[64],"0.79;":[65],"p=0.09).":[67],"both":[69],"studies,":[70],"randomization":[71],"stratified":[73,170],"by":[74,171],"visceral":[75,172],"status":[76,173,283,311],"slight":[78],"imbalances":[79,91],"some":[81],"covariates.":[82],"We":[83],"performed":[84],"MVA":[85],"to":[86,112,145],"assess":[87],"impact":[89],"and":[92,191,194,218],"prognostic":[93,192],"factors":[94],"on":[95,184],"Methods:":[97],"A:":[99],"Pts":[100,134],"(N=229)":[101],"\u22641":[103],"prior":[104,138],"chemo":[105,139,237],"regimen":[106],"were":[110,143,174,181],"randomized":[111,144,262],"CAP":[113,267],"(1,000":[114],"mg/m2":[115],"po,":[116,128,159],"twice":[117],"daily":[118],"[BID],":[119],"14":[120],"21":[122],"days)":[123],"(400":[126,157],"mg":[127,158],"BID)":[129,160],"or":[130,161,287,315,323,355,359],"PL.":[131,162],"B:":[133],"(N=237)":[135],"no":[137],"PAC":[146],"(90":[147],"mg/m2/wk":[148],"IV,":[149],"3":[150],"wk":[151,153],"on/1":[152],"off)":[154],"MVA:":[163],"Cox":[164],"proportional":[165],"hazards":[166],"models":[167],"used":[175],"each":[177],"study.":[178],"Additional":[179],"covariates":[180],"selected":[182],"based":[183],"degree":[185],"imbalance":[187],"between":[188],"study":[189],"arms":[190],"importance":[193],"retained":[195],"if":[196],"p":[198,278],"<0.15.":[199],"Results:":[200],"After":[201],"adjusting":[202,252],"covariates,":[204],"SOR+CAP":[205],"associated":[207],"a":[209,221],"36%":[210],"risk":[211,223],"reduction":[212,224],"vs":[213,225,321],"SOR+PAC":[219],"27%":[222],"B":[229,309],"(Table).":[230],"Conclusions:":[231],"Primary":[232],"analysis":[233],"favoring":[236],"PL":[241,304,348],"two":[243],"maintained":[250],"after":[251],"imbalances.":[254],"Overall":[255],"survival":[256],"data":[257],"are":[258],"pending.":[259],"A":[260,281],"large":[261],"III":[264],"trial":[265],"\u00b1":[268],"is":[270],"planned.":[271],"Retained":[272],"variables":[273],"HR":[274],"(95%":[275],"CI)":[276],"One-sided":[277],"value":[279],"Hormone":[282,310],"ER\u2014/PR\u2014":[284,312],"vs.":[285,296,303,313,332,340,347],"ER+":[286,314,322],"PR+":[288,316,324],"2.02":[289],"(1.38\u20132.96)":[290],"0.00015":[291],"Disease-free":[292,328],"interval":[293,329],"<2":[294],"y":[295,331,342],"2":[297],"y+":[298,334],"1.31":[299],"(0.92\u20131.87)":[300],"0.066":[301],"0.64":[305],"(0.45\u20130.91)":[306],"0.006":[307],"1.73":[317],"(1.16\u20132.56)":[318],"0.003":[319],"Unknown":[320],"1.58":[325],"(0.96\u20132.61)":[326],"0.04":[327,351],"<1":[330],"1":[333],"1.20":[335],"(0.85\u20131.71)":[336],"0.15":[337],"Age":[338],"50+":[339],"<50":[341],"0.83":[343],"(0.58\u20131.17)":[344],"0.14":[345],"0.73":[349],"(0.52\u20131.04)":[350],"Author":[352],"Disclosure":[353],"Employment":[354],"Leadership":[356],"Position":[357],"Consultant":[358],"Advisory":[360],"Role":[361],"Stock":[362],"Ownership":[363],"Honoraria":[364],"Research":[365],"Funding":[366],"Expert":[367],"Testimony":[368],"Other":[369],"Remuneration":[370],"Bayer,":[371],"Onyx":[372]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W61385997","counts_by_year":[{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}
